A monoclonal antibody drug, named evinacumab, with theability to target ANGPTL3 has developed, and it has been demonstratedthat this drug can reduce lipid levels through several mechanisms [68, 70],suggesting that targeting ANGPTL3 may be a compelling therapeutic optionfor the management of HoFH patients [71] and has an effect on LDL-C independentof LDLR  [72]. The gene discussed is ANGPTL3; the disease is homozygous familial hypercholesterolemia.